Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.

ABSTRACT: Contemporary in vivo and in vitro discovery platform technologies greatly increase the odds of identifying high-affinity monoclonal antibodies (mAbs) towards essentially any desired biologically relevant epitope. Lagging discovery throughput is the ability to select for highly developable mAbs with drug-like properties early in the process. Upstream consideration of developability metrics should reduce the frequency of failures in later development stages. As the field moves towards incorporating biophysical screening assays in parallel to discovery processes, similar approaches should also be used to ensure robust chemical stability. Optimization of chemical stability in the early stages of discovery has the potential to reduce complications in formulation development and improve the pote

SUBMITTER: Lu X 

PROVIDER: S-EPMC6343770 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature